Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

MMJ Recs

MARCH 16, 2024

Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.

Safety 52

Safety Hemp Research and Development Data 52

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

MMJ Recs

MARCH 20, 2024

Maryland medical cannabis dispensary services Maryland’s medical cannabis dispensaries offer comprehensive services tailored to meet the needs of registered patients. Trained dispensary staff assist patients in product selection, dosage recommendations, and consumption methods, ensuring personalized care and guidance.

Dispensary 52

Dispensary Programs Access Patients 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has the potential to reduce opioid dependence and addiction, leading to safer and healthier communities.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.

Safety 52

Safety Hemp Research and Development Data 52

Veriheal

JANUARY 18, 2024

In a revolutionary development that reflects the ever-changing healthcare arena, cannabis nursing has earned official recognition as a specialized field in nursing. Patient education is their primary focus, as they provide knowledgeable guidance on the therapeutic benefits and potential risks of cannabis.

Education 113

Education Therapy Patients Research and Development 113

Cannabis Law Report

JULY 19, 2021

We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including phase 3 large scale clinical trials.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

MMJ Recs

APRIL 30, 2024

From the moment a cannabis seed is planted to the point it reaches the hands of a patient, a complex and highly regulated process unfolds. These regulations aim to maintain quality control, prevent diversion to the illicit market, and ensure patient safety.

Cultivation 52

Cultivation Supply Chain Extraction Marijuana 52

Cannabis Law Report

APRIL 13, 2022

Delic Labs’ latest exemptions enable the Company to develop innovative analytical methods for psychedelic research. Last year, the lab also applied for a Dealer’s License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. .

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. These compounds may help reduce symptoms and improve the quality of life for patients.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JUNE 17, 2021

goodblend™ Texas , a retail brand of Parallel , one of the nation’s largest privately-held multi-state cannabis operators, today announced the launch of the first cannabinol (CBN) products for patients registered in the Texas Compassionate Use Program. goodblend™ Texas, a retail brand of Parallel.

Patients 97

Patients Programs Sleep Retail 97

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.

Patients 98

Patients Education Marijuana Therapy 98

MMJ Recs

MAY 9, 2024

As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

Canna Law Blog

SEPTEMBER 12, 2022

The regulations take the form of a decree issued by President Laurentino Cortizo Cohen, which “regulates the use and access to the product and its derivatives, for therapeutic, medical, veterinary, scientific and research purposes throughout the country.” The decree also establishes a patient registry.

Research and Development 89

Research and Development Safety Medicine Agriculture 89

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Today (30 May) at 09.30 Formula 1 THC is higher than CBD.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

AUGUST 22, 2021

Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.

Safety 52

Safety Cannabinoids Events Data 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges remain in ensuring equitable access to participation in the legal cannabis market and addressing disparities in ownership and representation.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?

Legislation 126

Legislation Clinical Trials Research and Development Access 126

Cannabis Law Report

SEPTEMBER 14, 2021

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances.

Research and Development 52

Research and Development Safety Patients Access 52

Kind Meds (Cannabis Education Blog)

OCTOBER 15, 2018

Why Patients Need Access to Pesticide-Free Marijuana. An individual who purchases marijuana illegally on the street has virtually no guarantee as to the quality or safety of the product. Marijuana growers worry about the safety and efficacy of their crops, so they have lobbied for pesticide approval in several states.

Patients 84

Patients Marijuana Research and Development Agriculture 84

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. The report further breaks down use by specific cultivars.

Data 105

Data Clinical Trials Research and Development Indica 105

The Cannigma

JUNE 2, 2023

The government remains steadfast in its commitment to maintaining strict drug laws to ensure public safety. The use of cannabis for medicinal purposes is not permitted, and there are no legal avenues for patients to access cannabis-based medications. Is weed legal in Singapore? No, weed is illegal in Singapore.

Law 52

Law Research and Development Consumption Therapy 52

MMJ Recs

FEBRUARY 23, 2024

The foundational framework was laid with the establishment of the Michigan Medical Marijuana Program in 2008, signalling the state’s commitment to providing legal access to cannabis for qualified patients. Patients benefit from a broad spectrum of cannabis products addressing various medical conditions.

Marijuana 52

Marijuana Dispensary Research and Development Supply Chain 52

Cannabis Law Report

SEPTEMBER 14, 2022

The regulations take the form of a decree issued by President Laurentino Cortizo Cohen, which “regulates the use and access to the product and its derivatives, for therapeutic, medical, veterinary, scientific and research purposes throughout the country.”. The decree also establishes a patient registry.

Research and Development 52

Research and Development Safety Medicine Agriculture 52

Medicinal Genomics

JANUARY 10, 2024

CannMed started in 2016, when Medicinal Genomics partnered with Dr. Raphael Mechoulam to host the leading researchers and clinicians in cannabinoid medicine at Boston’s Harvard Medical School. Look no further than the CannMed Advisory Board for evidence that the most esteemed clinicians and researchers make the trip to CannMed each year.

Research and Development 52

Research and Development Events Education Medicine 52

MMJ Recs

OCTOBER 5, 2023

With a growing number of MMJ dispensaries, a comprehensive set of laws, and a streamlined process for obtaining a medical marijuana card, the state has become a hub for patients seeking alternative treatments. Whether you’re a potential patient or simply curious about MMJ, we’re here to provide you with all the essential information!

Dispensary 52

Dispensary Patients Treatment Conditions 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

SEPTEMBER 1, 2021

This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89